Corvus touts ear­ly da­ta on T cell lym­phoma drug, makes PhI­II plans

Corvus Phar­ma­ceu­ti­cals said that its T cell lym­phoma drug helped shrink tu­mors in pa­tients whose can­cer had re­lapsed, ac­cord­ing to an ear­ly cut of da­ta re­leased Thurs­day morn­ing.

Of 20 evalu­able pa­tients, three had com­plete re­spons­es, and three had par­tial re­spons­es as of May 18. One pa­tient with a com­plete re­sponse and two with par­tial re­spons­es are still on Corvus’ drug, which is an ITK in­hibitor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER